Genetic Technologies Limited announced the Company has established a precision oncology division and announced its highly anticipated portfolio of new diagnostic tests under its geneType precision oncology brand. The proprietary-developed tests will provide invaluable information to medical oncologists, helping determine which therapies will have the most efficacious impact in treating a range of cancers including, melanoma, lung, pancreatic, colorectal, breast, ovarian and brain cancers. Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests.

Earlier detection of a range of cancers leads to significantly improved patient outcomes. These new tests will transform oncology diagnostics, companion diagnostics, and disease monitoring. A guideline-driven approach for reimbursement makes tests accessible and affordable for patients.

The global liquid biopsy and methylation market has a combined valuation of over USD 11 billion. The portfolio will include methylation tests, developed in collaboration with the University of Melbourne Department of Surgery, which identify unique features of the cancer such as methylation patterns. The range will also include solid tumour mutation tests to identify the molecular signature of tumours and detect mutations, and liquid biopsy tests to monitor disease progression.